Skip to main content
Premium Trial:

Request an Annual Quote

New Products: Phalanx's CytoOneArray

Premium

Phalanx Biotech recently launched its CytoOneArray.

The Taiwanese company designed the chromosomal microarray for prenatal and postnatal detection of microdeletions and microduplications related to congenital disorders, especially developmental and intellectual delay disorders. According to Phalanx, CytoOneArray is capable of detecting 264 clinically confirmed disease regions and 41 subtelomere regions.

CEO Shengwan Lee said in a statement that CytoOneArray is the "first in a series" of chromosomal microarray products, and noted that the release occured at a "time when cytogeneticists are adopting chromosomal microarray as a first-tier clinical diagnostic test."

To design CytoOneArray, Phalanx worked with "leading cytogeneticists" in Taiwan. Following a curation process of disease regions, the company designed probes to cover 90 percent of published microdeletions and microduplications associated with developmental and intellectual delay disorders.

BioArray News discussed Phalanx's entry into the chromosomal array market earlier this year (BAN 3/13/2012)

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.